

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3929423

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NOVARTIS VACCINES AND DIAGNOSTICS INC	06/15/2016
RECEIVING PARTY DATA	
Name:	GLAXOSMITHKLINE BIOLOGICALS SA
Street Address:	RUE DE L'INSTITUT 89
City:	RIXENSART
State/Country:	BELGIUM
Postal Code:	1330
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	8637044
Patent Number:	8168194
CORRESPONDENCE DATA	
Fax Number:	(610)270-6812
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6102706812
Email:	us_cipkop@gsk.com
Correspondent Name:	GLAXOSMITHKLINE
Address Line 1:	709 SWEDELAND ROAD
Address Line 2:	UW2220
Address Line 4:	KING OF PRUSSIA, PENNSYLVANIA 19406
ATTORNEY DOCKET NUMBER:	VN51798
NAME OF SUBMITTER:	CARLY MORROW
SIGNATURE:	/Carly Morrow/
DATE SIGNED:	06/22/2016
Total Attachments: 2	
source=VN51798 GEN Confirmatory Assignment#page1.tif	
source=VN51798 GEN Confirmatory Assignment#page2.tif	

CONFIRMATORY ASSIGNMENT

WE **NOVARTIS VACCINES AND DIAGNOSTICS INC** a company duly incorporated in the state of Delaware, and having a registered office at 2711 Centerville Road, Suite 400 Wilmington, Delaware 19808 United States of America do hereby declare that we are the sole owner of the following patents entitled "HIV TAT-CD4 HYBRID MOLECULES AND METHODS OF USE THEREOF"


Country	Application Date	Application Number	Grant Date	Patent Number
European Patent Convention	03-Feb-06	06734349 1	23-Jun-10	EP1893650
France	03-Feb-06	06734349 1	23-Jun-10	EP1893650
Italy	03-Feb-06	502010901874133	23-Jun-10	EP1893650
Netherlands	03-Feb-06	06734349 1	23-Jun-10	EP1893650
South Africa	03-Feb-06	2007/07138	26-Nov-08	2007/07138
United States	22-Mar-12	13/427234	28-Jan-14	8637044
United States	03-Feb-06	11/883696	01-May-12	8168194


Whereas in accordance with the Patent Assignment Agreement dated 26 February 2015 between **NOVARTIS VACCINES AND DIAGNOSTICS INC** and **NOVARTIS AG**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS VACCINES AND DIAGNOSTICS INC** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **NOVARTIS AG** of Lichtstrasse 35, 4056 Basel, Switzerland

And in accordance with the Intellectual Property Assignment Agreement dated 2 March 2015 between **NOVARTIS AG** and **GLAXOSMITHKLINE BIOLOGICALS SA**, for good and valuable consideration, the receipt of which is hereby acknowledged, we **NOVARTIS AG** have assigned the entire right, title and interest and from which priority may be claimed from one or more applications, or any division, continuation and continuation-in-part of said application to in and to said patent application and all countries in which this/ these application(s) are filed to **GLAXOSMITHKLINE BIOLOGICALS SA** of Rue de l'Institut 89, 1330 Rixensart, Belgium


Dated this 15 day of June 2016.


Signed for and on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC


Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC



Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS VACCINES AND DIAGNOSTICS INC

Signed for and on behalf of
NOVARTIS AG


Lorraine B. Ling
Authorized Signatory on behalf of
NOVARTIS AG


Theodore R. Furman
Authorized Signatory on behalf of
NOVARTIS AG

Signed for and on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA


William R. Majarian
Authorized Official on behalf of
GLAXOSMITHKLINE BIOLOGICALS SA